Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab for CTC reduction in NSCLC
NCT04648189Phase 2Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Planned start Jan 2022; status: withdrawn.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04648189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648189.